Literature DB >> 18574580

Local effects and mechanisms of antiarrhythmic peptide AAP10 in acute regional myocardial ischemia: electrophysiological and molecular findings.

Joanna Jozwiak1, Stefan Dhein.   

Abstract

Previously, it was shown that antiarrhythmic peptides and our lead substance AAP10 enhance electrical intercellular communication via gap junctions. Now, we wanted to elucidate whether AAP10 acts preferably in the ischemic area and the molecular mechanism of this peptide. Seventeen rabbit hearts were isolated, perfused according to Langendorff, and submitted to 30-min local ischemia by LAD occlusion with/without AAP10 (50 nM). Electrophysiology was assessed by 256 channel epicardial mapping. Finally, the ischemic zone, border zone, and non-ischemic zone were excised, and the cardiac gap junction protein connexin43 (Cx43), its phosphorylation state, and the distribution at the polar and lateral membrane of cardiomyocytes were determined by Western blot and immunofluorescence. Ischemia led to a decrease in activation recovery interval (ARI) homogeneity, which could be completely prevented by AAP10. Moreover, ischemia-induced activation wave slowing in the ischemic border zone was antagonized by AAP10. In ischemic center and border zone, but not in the non-ischemic area, (phospho-Cx43/dephospho-Cx43)-ratio decreased. This was also significantly antagonized by AAP10. Serine 368 was identified as one phosphorylation site for the activity of AAP10. In the non-ischemic area, AAP10 had no influence on Cx43 phosphorylation state. Interestingly, ischemia led to a loss of Cx43 from the cell poles and lateral sides in the ischemic area and border zone. AAP10 completely prevented the ischemia-induced decrease in polar Cx43 presence. In the ischemic area, AAP10 prevents from ischemia-induced Cx43 dephosphorylation and loss of Cx43 from the gap junction at cell poles and in parallel prevents the decrease in ARI homogeneity and attenuates ischemia-induced slowing of activation wave propagation. The AAP10 action seems confined to the ischemic area.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18574580     DOI: 10.1007/s00210-008-0317-4

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  48 in total

1.  Structure-activity relationships of novel peptides related to the antiarrhythmic peptide AAP10 which reduce the dispersion of epicardial action potential duration.

Authors:  R Grover; S Dhein
Journal:  Peptides       Date:  2001-07       Impact factor: 3.750

2.  Spread of activation in the left ventricular wall of the dog. II. Activation conditions at the epicardial surface.

Authors:  D DURRER; L H VAN DER TWEEL
Journal:  Am Heart J       Date:  1954-02       Impact factor: 4.749

3.  Block of intercellular communication: interaction of intracellular H+ and Ca2+.

Authors:  J M Burt
Journal:  Am J Physiol       Date:  1987-10

Review 4.  Cardiac ischemia and uncoupling: gap junctions in ischemia and infarction.

Authors:  Stefan Dhein
Journal:  Adv Cardiol       Date:  2006

5.  Pharmacological modification of gap junction coupling by an antiarrhythmic peptide via protein kinase C activation.

Authors:  Stephan Weng; Melani Lauven; Thomas Schaefer; Lioudmila Polontchouk; Rajiv Grover; Stefan Dhein
Journal:  FASEB J       Date:  2002-05-08       Impact factor: 5.191

6.  Redistribution of connexin43 in regional acute ischemic myocardium: influence of ischemic preconditioning.

Authors:  Friedrich Vetterlein; Christian Mühlfeld; Cenk Cetegen; Rolf Volkmann; Christina Schrader; Gerhard Hellige
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-03-24       Impact factor: 4.733

7.  Intracellular Ca2+, intercellular electrical coupling, and mechanical activity in ischemic rabbit papillary muscle. Effects of preconditioning and metabolic blockade.

Authors:  L R Dekker; J W Fiolet; E VanBavel; R Coronel; T Opthof; J A Spaan; M J Janse
Journal:  Circ Res       Date:  1996-08       Impact factor: 17.367

8.  Reversible connexin 43 dephosphorylation during hypoxia and reoxygenation is linked to cellular ATP levels.

Authors:  Mark S Turner; Guy A Haywood; Peter Andreka; Lijing You; Patricia E Martin; W Howard Evans; Keith A Webster; Nanette H Bishopric
Journal:  Circ Res       Date:  2004-09-09       Impact factor: 17.367

9.  Protective role of gap junctions in preconditioning against myocardial infarction.

Authors:  Tetsuji Miura; Yoshito Ohnuma; Atsushi Kuno; Masaya Tanno; Yoshihiko Ichikawa; Yuichi Nakamura; Toshiyuki Yano; Takayuki Miki; Jun Sakamoto; Kazuaki Shimamoto
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-09-18       Impact factor: 4.733

10.  Changes in phosphorylation of connexin43 in rats during acute myocardial hypoxia and effects of antiarrhythmic peptide on the phosphorylation.

Authors:  Rong Wang; Cuntai Zhang; Yanfei Ruan; Nian Liu; Lin Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-06
View more
  22 in total

1.  A peptide mimetic of the connexin43 carboxyl terminus reduces gap junction remodeling and induced arrhythmia following ventricular injury.

Authors:  Michael P O'Quinn; Joseph A Palatinus; Brett S Harris; Kenneth W Hewett; Robert G Gourdie
Journal:  Circ Res       Date:  2011-01-27       Impact factor: 17.367

2.  Arrhythmogenic effects by local left ventricular stretch: effects of flecainide and streptomycin.

Authors:  Stefan Dhein; Christine Englert; Stephanie Riethdorf; Martin Kostelka; Pascal Maria Dohmen; Friedrich-Wilhelm Mohr
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-05-27       Impact factor: 3.000

Review 3.  Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptides.

Authors:  Stefan Dhein; Anja Hagen; Joanna Jozwiak; Anna Dietze; Jens Garbade; Markus Barten; Martin Kostelka; Friedrich-Wilhelm Mohr
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11-27       Impact factor: 3.000

Review 4.  Specific Cx43 phosphorylation events regulate gap junction turnover in vivo.

Authors:  Joell L Solan; Paul D Lampe
Journal:  FEBS Lett       Date:  2014-02-04       Impact factor: 4.124

Review 5.  Connexins in the Heart: Regulation, Function and Involvement in Cardiac Disease.

Authors:  Antonio Rodríguez-Sinovas; Jose Antonio Sánchez; Laura Valls-Lacalle; Marta Consegal; Ignacio Ferreira-González
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

6.  The gap junction modifier ZP1609 decreases cardiomyocyte hypercontracture following ischaemia/reperfusion independent from mitochondrial connexin 43.

Authors:  Kerstin Boengler; Marko Bulic; Rolf Schreckenberg; Klaus-Dieter Schlüter; Rainer Schulz
Journal:  Br J Pharmacol       Date:  2017-05-10       Impact factor: 8.739

7.  Novel pharmacological approaches for antiarrhythmic therapy.

Authors:  Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-01-15       Impact factor: 3.000

Review 8.  Intercalated discs: cellular adhesion and signaling in heart health and diseases.

Authors:  Guangze Zhao; Ye Qiu; Huifang M Zhang; Decheng Yang
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

9.  Desipramine prevents cardiac gap junction uncoupling.

Authors:  Joanna Jozwiak; Anna Dietze; Rajiv Grover; Alex Savtschenko; Christian Etz; Friedrich W Mohr; Stefan Dhein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-09-11       Impact factor: 3.000

10.  On the different roles of AT1 and AT2 receptors in stretch-induced changes of connexin43 expression and localisation.

Authors:  Aida Salameh; Daniel Apel; Jorge Gonzalez Casanova; Sandy von Salisch; Friedrich-Wilhelm Mohr; Ingo Daehnert; Stefan Dhein
Journal:  Pflugers Arch       Date:  2012-09-25       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.